The objective of the present experiment was to examine the effect of substituting different quantities of soyabean protein for casein on renal function and lipid metabolism in rats with chronic renal failure induced by a five-sixths nephrectomy. Experimental animals were subjected to a nephrectomy and fed either casein or soyabean protein (200 or 100 g/kg diet). The diets were isoenergetic with identical fat, Na, K and P contents. Rats ingesting 200 g casein/kg diet showed a significantly (P, 0·05) accelerated course of chronic renal failure, while the soyabean-protein groups showed retarded progression of the experimentally induced renal disease and hypercholesterolaemic effects. Rats in the low-soyabean-protein diet (100 g/ kg) also demonstrated increased serum albumin and decreased serum triacylglycerol, total cholesterol concentrations and blood urea-N; however, the low-casein diet significantly (P, 0·05) increased serum triacylglycerol. Results of the present study show that the replacement of casein by soyabean protein was related to the rate of progression of renal failure and improvement in lipid profiles in serum of five-sixths nephrectomized rats.
Soyabean-protein intake has a profound effect on renal function. Evidence supports the notion that high-animalprotein ingestion accelerates the progression of chronic renal failure (CRF), because it induces glomerular hyperfiltration by causing increases in renal blood flow and inevitable glomerular sclerosis, and it is associated with increased urinary protein excretion (Brenner et al. 1982) . On the other hand, administration of an equal quantity of soyabean protein does not alter any of these variables (Kenner et al. 1985; Williams et al. 1987; Kontessis et al. 1995 Kontessis et al. , 1990 . Abnormal lipid metabolism is also a common symptom in patients with renal disease (Appel, 1991) . A meta-analysis of the effects of soyabean-protein intake showed significant decreases in serum cholesterol and triacylglycerol compared with effects of animal-protein intake (Anderson et al. 1995 (Anderson et al. , 1999 .
However, in those trials it was difficult to know if a normal-soyabean-protein diet could retard the progression of CRF, and the benefits of soyabean protein intake for lowering lipid levels in CRF remain uncertain. The purposes of the present study were to investigate the effect of different quantities of soyabean protein and casein on renal function and lipid metabolism in rats with CRF induced by a five-sixths nephrectomy and to determine whether changes in the dietary protein source were related to the rate of progression of renal failure and to lipid profiles in serum.
Materials and methods

Animals and diets
Fifty-two male Sprague-Dawley rats weighing 200 -250 g were used in the present study. Animals were housed in individual cages with free access to tap water and received the same diet (standard diet) for 1 week. One week later, forty rats underwent a five-sixths nephrectomy, consisting of the surgical excision of approximately two-thirds of the left kidney, while the entire right kidney was removed. Twelve rats underwent a sham operation, consisting of a laparotomy and manipulation of the kidneys, but without destruction of renal tissue. After this, experimental animals (with the five-sixths nephrectomy) were assigned randomly to four groups (A -D) and were fed either casein (ICN Biochemicals, Aurora, OH, USA) or soyabean-protein isolate (Protein Technologies International, St Louis, MO, USA), at 200 or 100 g/kg diet: group A received 200 g casein/kg; group B 100 g casein/kg; group C 200 g soyabean-protein isolate/kg; group D 100 g soyabean-protein isolate/kg. Control animals were assigned to two groups fed either 200 g casein/kg (group E) or 200 g soyabean-protein isolate/kg diet (group F). The diets were isoenergetic and contained equal amounts of fat, mineral, and vitamin supplements (AIN-76; ICN Biochemicals). The compositions of the diets are shown in Table 1 . Food powder (30 g) was prepared for each animal daily, and the amount ingested was determined by weighing the remaining food.
Data collection
Animals were weighed each week. At 2-week intervals, overnight fasting tail-vein blood and 3 d of 24 h urine were collected. All samples were analysed using a Hitachi 7170S Autoanalyser (Tokyo, Japan). Plasma samples were analysed for albumin, total cholesterol, triacylglycerol, creatinine and urea N; urine was analysed for creatinine, urea-N and protein. Total cholesterol and triacylglycerol were determined after enzymatic reaction with peroxidases (Allain et al. 1974; Spayd et al. 1978) . Albumin was determined by the Bromocresol Green method (Doumas et al. 1971) , and creatinine by the Jaffé reaction method (Fabiny & Ertingshausen, 1971; Soldin et al. 1978) . Urea-N was determined after enzymatic reaction with urease and glutamate dehydrogenase (Kaltwasser & Schlegel, 1966) . Urine protein was determined by the Lowry method (Lowry et al. 1951) . The creatinine clearance rate was calculated by the following equation: (urine creatinine concentration (mg/l) £ urine output (ml))/(plasma creatinine concentration (mg/l) £ 1440 (min)).
Blood pressure was measured at the beginning and after 12 weeks of the study by the tail-cuff method using a programmed electro-sphygmomanometer (Model 179; IITC Life Science, Woodland Hills, CA, USA). Rats were kept in a dark, warm ð25^28CÞ and quiet environment during measurements. Rats were placed in an animal restrainer several minutes before beginning the test, and were given plenty of time to acclimatize to the device. At least five readings were recorded, the maximum and minimum values were discarded, and average systolic blood pressure value was calculated from the remaining three values. Rats were killed 24 weeks later. During the study period, if animals developed renal failure severe enough to threaten survival, we bled the tail-vein blood of moribund animals and then killed them.
Statistical analysis
One-way ANOVA was used to test the significance of differences between control and experimental animals. Two-way ANOVA and Fisher's least significant difference test were used to test the significance of differences in the quantity and quality of protein between experimental animals. Results are expressed as mean values with their standard errors. A P value of , 0·05 was taken as the level of statistical significance. Animals requiring premature killing were excluded from those comparisons.
Results
Food intake, weight gain and serum albumin
Daily food intake of the experimental groups and control groups did not differ. Animals in group A gained significantly (P, 0·05) less weight and had a lower feed efficiency compared with those of the other groups ( Table 2 ). The weight gain and feed efficiency did not significantly differ among the other experimental groups (groups B, C and D) or the control groups (groups E and F). Serum albumin concentrations of animals in group A were significantly (P, 0·05) lower than those of animals in group B and D and the control groups (Fig. 1) . Animals in group C had lower concentrations of serum albumin than did animals in group D and the control groups 20 weeks after the nephrectomy, and there were no significant differences in serum albumin concentrations among groups B and D and the control groups.
Renal function
Plasma creatinine and blood urea-N values were markedly elevated in the experimental groups after the nephrectomy and were significantly (P, 0·05) higher than those of the control groups. Blood urea-N in animals in group A was significantly (P, 0·05) higher than that of the other experimental animals throughout the experimental period. There was no significant difference in blood urea-N among groups B, C and D, except for those values between 2 and 12 weeks (P, 0·05, Fig. 2 ).
The urea-N excretion of animals ingesting the 200 g protein/kg diets (groups A, C and E) was significantly (P, 0·05) higher than that of animals ingesting the 100 g protein/kg diets (groups B, D and F), but did not differ between experimental groups with the same quantity level of protein (Table 3) . Proteinuria was significantly (P, 0·05) greater in group A than in groups B and D; there were no significant differences among groups B, C and D. The initial and final serum creatinine levels did not differ among the experimental groups (Table 3 ). The average slopes of the reciprocal of plasma creatinine v. time by linear regression analysis were found to be: group A2 0·036 (SEM 0·008); group B2 0·020 (SEM 0·002); group C2 0·030 (SEM 0·005); group D2 0·021 (SEM 0·002).
The slope was significantly steeper in group A than in groups B and D (P, 0·05), and there were no significant differences between groups A and C or among groups B, C and D (Fig. 3) . The creatinine clearance rate of group A was significantly (P, 0·05) less than that in the other experimental groups, and there were no differences among groups B, C and D.
Plasma lipid profiles and blood pressure
Plasma total cholesterol of animals in group D 8 weeks after the nephrectomy was significantly (P, 0·05) lower than that in group A; plasma total cholesterol of animals in groups B and D differed significantly (P, 0·05) from that of group A 24 weeks after the nephrectomy. Among groups B, C and D, there were no significant differences in total cholesterol (Fig. 4) . The plasma triacylglycerol concentration of group B was significantly (P, 0·05) higher than those of the other experimental animals, and the greatest concentration occurred between 10 and 16 weeks after the nephrectomy. The plasma triacylglycerol concentration in group C was significantly (P, 0·05) lower than that of group B, and the concentration in group D was also significantly (P, 0·05) lower than that in group B 8 weeks after the nephrectomy. There were no significant differences among groups A, C and D (Fig. 5) . Systolic blood pressure of rats did not significantly differ among each group. After 12 weeks, systolic blood pressure was greater in the experimental groups than in the control groups; the systolic blood pressure of group A was significantly (P, 0·05) greater than those of the other experimental groups, and there were no significant differences among groups B, C and D (Table 3) .
Discussion
The results of the present study show that rats with CRF, induced by a five-sixths nephrectomy ingesting, 100 g casein or 100 g soyabean protein/kg diet both reduced the rate of decrease in renal function compared with that of rats fed 200 g casein/kg diet, as established by plotting the reciprocal of plasma creatinine v. time and by the creatinine clearance rate. This is consistent with findings of previous studies in which dietary protein restriction retarded the progression of renal dysfunction in experimental animals (Kenner et al. 1985; Williams et al. 1987; Ihle et al. 1989 ) and human subjects (Soroka et al. 1998) . Animals in the experimental groups ingesting soyabean protein had an improved lipid metabolism compared with those ingesting animal protein. The mechanisms of the hypocholesterolaemic effects of soyabean protein are still under investigation. Some researchers have suggested that soyabean protein contains a different amino acid composition (Huff et al. 1980; Vahouny et al. 1985) , a special protein fraction (Lovati et al. 1992; , or other biologically active constituents such as isoflavones, or a combination of factors that lead to altered lipoprotein metabolism. These studies have indicated that when soyabean protein is fed to human subjects, cholesterol absorption and bile acid reabsorption are impaired (Huang et al. 1993; Gerhardt & Gallo, 1998) , and changes in endocrine status occur involving thyroid hormone, insulin and glucagon (Forsythe, 1990 (Forsythe, , 1995 Sanchez & Hubbard, 1991; Barth & Pfeuffer, 1998) , which are associated with increased clearance of cholesterol and which affect cholesterol metabolism. Soyabean isoflavones, whose structures are similar to those of oestrogens interact with oestrogen receptors and may decrease serum cholesterol concentrations by similar mechanisms (Anderson et al. 1995) . However, the increase in cholesterol levels may also be due to casein being used as the protein component of the diets. Casein was found to be more hypercholesterolaemic than soyabean protein (Sirtori et al. 1977; Carroll, 1978) , and the degree of hypercholesterolaemia was increased by adding casein or a casein amino acid mixture to the diet (Terpstra et al. 1981; Kurowska & Carroll, 1990) .
In the present study, diets of both the 100 g protein/kg groups contained a higher level (627 g/kg) of maize starch than those of the 200 g protein/kg groups (527 g/ kg). We found that the 100 g soyabean protein/kg group did not differ significantly from the 200 g protein/kg groups in serum triacylglycerol concentration, but the group consuming the 100 g casein/kg diet had significantly (P, 0·05) increased serum triacylglycerol. Soyabean protein may affect triacylglycerol metabolism by suppression of fatty acid synthesis and stimulation of lipolysis. Iritarni et al. (1986 Iritarni et al. ( , 1996 reported that soyabean protein suppresses hepatic lipogenic enzyme expression, and enzymes for the synthesis of triacylglycerol were markedly lower in rats fed a soyabean-protein diet compared with those fed casein.
Although there were no significant differences found in renal function between the 200 g soyabean protein and 200 g casein protein/kg groups by the slopes of the reciprocal of plasma creatinine v. time, rats ingesting 200 g soyabean protein/kg had lower proteinuria, blood urea-N, systolic blood pressure and lipid profiles than those ingesting the 200 g casein/kg diet. The creatinine clearance rate in the 200 g soyabean protein/kg group was significantly (P, 0·05) higher than that in the 200 g casein/kg group. Both creatinine clearance rate and the slopes did not differ significantly among the 200 g soyabean protein, 100 g casein and 100 g soyabean protein/kg diets. These results indicate that an unrestricted soyabean-protein diet still had some advantages over an animal-protein diet in terms of renal failure. The results of our present study are consistent with a previous observation that animals fed soyabean protein had much slower progression of renal failure than animals fed casein (Williams et al. 1987) . Kontessis et al. (1995) suggested that substituting soyabean protein for animal protein would be effective in reversing the progression of diabetis mellitus-induced nephropathy in human subjects. The mechanism underlying how a soyabean-protein diet retards the slow progressive effect of CRF has not been fully established. Studies have indicated that soyabean protein does not alter postprandial renal blood flow or glomerular filtration rates, whereas animal protein significantly increases these indices (Kontessis et al. 1990; Pecis et al. 1994) . Animals ingesting soyabean protein were noted to have less proteinuria, less renal hypertrophy, less histological damage to the kidneys and improved survival rates (Williams et al. 1987) . Possible ameliorating effects of soyabean protein might induce an alteration in glomerular haemodynamics similar to the effect of protein restriction. Soyabean protein contains small amounts of the amino acids glutamine, proline, glycine, alanine and trytophan that are predominately metabolized by the kidney, where they exert vasodilatory effects (Woods, 1993) and can reduce the extent of proteinuria (Kaysen & Kopple, 1983) . Furthermore, soyabean protein contains an angiotensin-converting enzyme inhibitor peptide (Kinoshita et al. 1993 ) and isoflavones, which have anti-inflammatory potential and therefore may also be contributing factors. Therefore, the benefit of a soyabean-protein diet against the progression of CRF may be due to a consequence of components absent from soyabean protein, but present in casein.
The results of the present study also showed that a 200 g soyabean protein/kg diet increased serum albumin and weight gain, and decreased blood urea-N when compared with the 200 g casein/kg diet. There is impressive evidence that a soyabean-protein diet may be quite effective in ameliorating uraemic symptoms and preventing some of the complications of CRF. Previous studies have shown that soyabean protein has a lower nutritive value compared with casein (Drouliscos & Bowland, 1969) . However, soyabean protein is now recognized as a complete protein, using the protein digestibility-corrected amino acid score that has been adopted as an alternative method for evaluating protein quality (Food and Drug Administration, 1991; Young, 1991) . In the present study, animals ingesting soyabean protein tended to have increased weight gain, greater feed efficiency and higher serum albumin than those ingesting casein. It is possible that diets supplemented with methionine and/or soyabean protein are relatively low in S-amino acids that may provide an advantage in ameliorating acidosis (Chan, 1974; Remer & Manz, 1994 ). An increase in serum albumin was also associated with isoflavones, in particular genistein, which has favourable effects by attenuating the inflammatory cascade (Atluru & Atluru, 1991; Anderson et al. 1995) . The hypoalbuminaemia of CRF patients is often related to inflammation (Stenvinkel et al. 2000) .
In conclusion, the present study indicated that animals fed 200 g casein/kg diet had significantly (P, 0·05) accelerated progression of CRF and increased serum total cholesterol. The low-soyabean-protein diet (100 g/kg) produced no increase in serum triacylglycerol compared with 100 g casein/kg diet, and rats consuming the low-soyabean diet gained significantly (P, 0·05) more weight and had higher serum albumin concentrations, and lower total cholesterol and blood urea-N than did those consuming 200 g casein/kg diet. We also found that unrestricted soyabean protein (200 g/ kg) can reduce the progression of CRF and hypercholesterolaemia when compared with casein. These findings provide evidence for the hypothesis that changes in types of dietary protein source are related to the rate of progression of CRF and changes in lipid profiles in serum. All of these features may be helpful during the predialysis phase of treatment for CRF. Further clinical studies are needed to clarify the effects responsible in human subjects for changes in renal function and lipid metabolism that we observed in fivesixths nephrectomized rats.
